AbbVie suffers fresh setback with lung cancer drug Rova-TAbbVie has suffered a further setback with its oncology drug Rova-T, after early data from a lung cancer Share XAbbVie suffers fresh setback with lung cancer drug Rova-Thttps://pharmaphorum.com/news/abbvie-suffers-fresh-setback-with-lung-cancer-drug-rova-t/
NHS funds BMS’ Opdivo to prevent skin cancer returningNICE has recommended interim NHS funding for Bristol-Myers Squibb’s cancer immunotherapy, Opdivo to prevent early stage skin cancer Share XNHS funds BMS’ Opdivo to prevent skin cancer returninghttps://pharmaphorum.com/news/nhs-funds-bms-opdivo-to-prevent-skin-cancer-returning/
Astellas scores first US blood cancer approval with XospataThe FDA has approved Astellas’ Xospata for certain patients with acute myeloid leukaemia – the company’s first drug Share XAstellas scores first US blood cancer approval with Xospatahttps://pharmaphorum.com/news/astellas-scores-first-us-blood-cancer-approval-with-xospata/
NICE approves Bayer’s liver cancer drugNICE has given Bayer’s advanced liver cancer therapy Stivarga (regorafenib) the go-ahead after it undertook a rapid review Share XNICE approves Bayer’s liver cancer drughttps://pharmaphorum.com/news/nice-approves-bayers-liver-cancer-drug/
EU approves Kyowa Kirin’s drug for rare lymphomaThe European Commission has approved Poteligeo (mogamulizumab), a treatment for rare types of non-Hodgkin’s lymphoma. The drug is Share XEU approves Kyowa Kirin’s drug for rare lymphomahttps://pharmaphorum.com/news/eu-approves-kyowa-kirins-drug-for-rare-lymphoma/
Bayer/Loxo drug approved in cancers with certain mutationThe FDA has approved Bayer and Loxo’s Vitravki (larotrectinib) for adults and children whose cancers have a specific Share XBayer/Loxo drug approved in cancers with certain mutationhttps://pharmaphorum.com/news/bayer-loxo-drug-approved-in-cancers-with-certain-mutation/
NHS lags best performers in cancer care – reportThe performance of NHS cancer services in England is lagging behind those of comparable countries, according to a Share XNHS lags best performers in cancer care – reporthttps://pharmaphorum.com/news/nhs-lags-best-performers-in-cancer-care-report/
J&J shares fall after court refuses to block Zytiga genericsJohnson & Johnson’s share price took a beating this week after the US appeals court declined its bid Share XJ&J shares fall after court refuses to block Zytiga genericshttps://pharmaphorum.com/news/jj-shares-fall-after-court-refuses-to-block-zytiga-generics/
Thousands to benefit as NHS funds Keytruda lung cancer comboNICE has said MSD’s cancer immunotherapy, Keytruda, should receive interim funding on the NHS in certain patients with Share XThousands to benefit as NHS funds Keytruda lung cancer combohttps://pharmaphorum.com/news/thousands-to-benefit-as-nhs-funds-keytruda-lung-cancer-combo/
Novartis focusing on cutting CAR-T costs ahead of EU launchesNovartis is focusing on cutting manufacturing costs for its CAR-T cancer cell therapy as the company launches it Share XNovartis focusing on cutting CAR-T costs ahead of EU launcheshttps://pharmaphorum.com/news/novartis-focusing-on-cutting-car-t-costs-ahead-of-eu-launches/
AstraZeneca searching for Pascal Soriot successor – reportAstraZeneca is looking for a successor to CEO Pascal Soriot just in case he decides to move on, Share XAstraZeneca searching for Pascal Soriot successor – reporthttps://pharmaphorum.com/news/astrazeneca-searching-for-pascal-soriot-successor-report/
Novartis’ CAR-T cancer drug available on NHS to young peopleNovartis’ cutting-edge CAR-T therapy Kymriah has officially become available on the NHS for young people with blood cancer. Share XNovartis’ CAR-T cancer drug available on NHS to young peoplehttps://pharmaphorum.com/news/novartis-car-t-cancer-drug-available-on-nhs-to-young-people/
AstraZeneca’s immunotherapy fails in key lung cancer trialAstraZeneca’s immunotherapy combination including its checkpoint inhibitor drug Imfinzi has failed to improve overall survival in a first-line Share XAstraZeneca’s immunotherapy fails in key lung cancer trialhttps://pharmaphorum.com/news/astrazenecas-imfinzi-fails-in-key-lung-cancer-trial/
Blueprint eyes quick filing for GIST drug avapritinibBlueprint Medicines has new data for its lead cancer drug avapritinib in gastrointestinal stromal tumours (GIST) that set Share XBlueprint eyes quick filing for GIST drug avapritinibhttps://pharmaphorum.com/news/blueprint-eyes-quick-filing-for-gist-drug-avapritinib/
GSK begins clinical trials of pancreatic cancer combinationGlaxoSmithKline plans to carry out clinical trials on its pancreatic drug hopeful, GSK547, following promising results when treating Share XGSK begins clinical trials of pancreatic cancer combinationhttps://pharmaphorum.com/news/gsk-begins-clinical-trials-of-pancreatic-cancer-combination/
